Subutex® is a single entity
buprenorphine product and Suboxone® is a combination product with
buprenorphine and naloxone in a 4:1 ratio, respectively. After reviewing all the available data and receiving a schedule III recommendation from the Department of Health and Human Services (DHHS), the DEA placed buprenorphine and all products containing buprenorphine into schedule III in 2002. Since 2003, diversion, trafficking and abuse of buprenorphine have become more common in the United States.